MGTA - マジェンタ・セラピュ―ティクス (Magenta Therapeutics Inc.)

MGTAのニュース

   Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September  2020/09/11 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences: Cantor Virtual Global Healthcare Conference, presentation at 8:00 a.m. ET on Wednesday, September 16 Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit, presentation at 10:50 a.m.
   Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer  2020/09/02 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition from Chief Operating and Financial Officer to a
   ArcherDX Appoints Jason Ryan to Board of Directors  2020/05/07 13:00:00 PR Newswire
BOULDER, Colo., May 7, 2020 /PRNewswire/ -- ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief Operating and Financial Officer at Magenta Therapeutics and former Chief Financial Officer at Foundation Medicine, to the company's Board of Directors and as the Chair of the…
   AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update  2020/05/07 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our strong progress has continued, as evidenced by recently announced collaborations with Saladax Biomedical, Inc. and Magenta Therapeutics, which highlight our commitment to leading innovation in the lentiviral gene th
   AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies  2020/05/06 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIO’s investigational lentiviral gene therapies. The collaboration will combine AVROBIO’s leadership in lentiviral gene therapies with Magenta’s expertise in ADC-based cond
   Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September  2020/09/11 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences: Cantor Virtual Global Healthcare Conference, presentation at 8:00 a.m. ET on Wednesday, September 16 Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit, presentation at 10:50 a.m.
   Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer  2020/09/02 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition from Chief Operating and Financial Officer to a
   ArcherDX Appoints Jason Ryan to Board of Directors  2020/05/07 13:00:00 PR Newswire
BOULDER, Colo., May 7, 2020 /PRNewswire/ -- ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief Operating and Financial Officer at Magenta Therapeutics and former Chief Financial Officer at Foundation Medicine, to the company's Board of Directors and as the Chair of the…
   AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update  2020/05/07 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our strong progress has continued, as evidenced by recently announced collaborations with Saladax Biomedical, Inc. and Magenta Therapeutics, which highlight our commitment to leading innovation in the lentiviral gene th
   AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies  2020/05/06 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIO’s investigational lentiviral gene therapies. The collaboration will combine AVROBIO’s leadership in lentiviral gene therapies with Magenta’s expertise in ADC-based cond
   ArcherDX Appoints Jason Ryan to Board of Directors  2020/05/07 13:00:00 PR Newswire
BOULDER, Colo., May 7, 2020 /PRNewswire/ -- ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief Operating and Financial Officer at Magenta Therapeutics and former Chief Financial Officer at Foundation Medicine, to the company's Board of Directors and as the Chair of the…
   AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update  2020/05/07 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our strong progress has continued, as evidenced by recently announced collaborations with Saladax Biomedical, Inc. and Magenta Therapeutics, which highlight our commitment to leading innovation in the lentiviral gene th
   AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies  2020/05/06 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIO’s investigational lentiviral gene therapies. The collaboration will combine AVROBIO’s leadership in lentiviral gene therapies with Magenta’s expertise in ADC-based cond
   Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?  2019/10/09 12:14:00 Zacks Investment Research
Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
   Magenta Therapeutics: Targeted Conditioning Agents Drive Long-Term Upside  2019/05/29 21:37:20 Seeking Alpha

calendar